I agree with your opinion as being the most plausi
Post# of 148290
I am mostly wondering though why non-CCR5delta BMT cannot cure patients with on HAART with undetectable viral load, but they think leronlimab may be able to do so .
Again maybe leronlimab is not only safer but also more potent against CCR5 HIV through its mechanism of action and longer half-life (10 days versus 1-2?) like your said which thereby subdues the active HIV hidden reservoirs more effectively.